Study on the association between plasma fibrinogen level and clinicopathological characteristics of prostate cancer

doi:10.3877/cma.j.issn.1674-3253.2020.01.004

Abstract

Abstract:

Objective

To analyze the relationship between plasma fibrinogen level and clinicopathological characteristics of prostate cancer. The value of plasma fibrinogen in early progress of prostate cancer was investigated.

Methods

A retrospective analysis of clinical and pathological data from 456 patients with prostate cancer(PCa) and 322 patients with benign prostatic hyperplasia(BPH) in Zhujiang Hospital who met the study criteria from January 2006 to December 2017 was performed. Age, body mass index (BMI), fibrinogen (FIB), Gleason score, total prostate specific antigen (tPSA), free prostate specific antigen (fPSA), free prostate specific antigen percentage (f/tPSA), clinical T stage (cT), presence or absence of lymph node metastasis, presence or absence of bone metastasis and risk stratification were collected and analyzed. SPSS 19.0 software package was used to analyze the correlation between the fibrinogen and the above indexes.

Results

The preoperative plasma FIB median in group PCa and BPH were 3.52 g/L (IQR, 2.97-4.35) and 3.12 g/L (IQR, 2.61-3.45), respectively. The plasma FIB was significantly increased in patients with PCa compared to patients with BPH (P<0.05). The preoperative plasma fibrinogen level was significant positively correlated with age, tPSA, Gleason score, cT stage (P<0.05).

Conclusion

Preoperative plasma fibrinogen level in patients with prostate cancer was associated with tumor pathological score, clinical T stage and related serum indicators, which can be combined with relevant imaging and laboratory examination results to predict the disease progression and outcome of patients.

Key words: Prostate cancer, Fibrinogen level, Pathologic characteristics, Disease progression

Qu Leng, Wei Su, Jun Li, Shuo Wang, Weian Zhu, Yu Wang, Chuanyin Li, Bingkun Li, Xingqiao Wen, Xiangming Mao. Study on the association between plasma fibrinogen level and clinicopathological characteristics of prostate cancer[J]. Chinese Journal of Endourology(Electronic Edition), 2020, 14(01): 12-15.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2020.01.004

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2020/V14/I01/12

Figures/Tables 4

References 19

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in china, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2]	闫贻忠，冯凯旋，王新宇, 等. 新疆石河子地区2009～2017年前列腺癌流行趋势分析[J]. 中华男科学杂志, 2019, 25(1): 35-40.
[3]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018 [J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[4]	Ross RW, Xie W, Regan MM, et al. Efficacy of androgen deprivation therapy (adt) in patients with advanced prostate cancer: Association between gleason score, prostate-specific antigen level, and prior adt exposure with duration of adt effect [J]. Cancer, 2008, 112(6): 1247-1253.
[5]	Pichler M, Dalpiaz O, Ehrlich GC, et al. Validation of the preoperative plasma fibrinogen level as a prognostic factor in a european cohort of patients with localized upper tract urothelial carcinoma [J]. J urol, 2014, 191(4): 920-925.
[6]	Wang J, Liu H, Shao N, et al. The clinical significance of preoperative plasma fibrinogen level and platelet count in resectable esophageal squamous cell carcinoma[J]. World J Surg Oncol, 2015, 13(1): 157.
[7]	Perisanidis C, Psyrri A, Cohen EE, et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: A systematic review and meta-analysis [J]. Cancer Treat Rev, 2015, 41(10): 960-970.
[8]	Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013 [J]. Eur Urol, 2014, 65(1): 124-137.
[9]	Lee S, Huh SJ, Oh SY, et al. Clinical significance of coagulation factors in operable colorectal cancer [J]. Oncol lett, 2017, 13(6): 4669-4674.
[10]	Zhang F, Wang Y, Sun P, et al. Fibrinogen promotes malignant biological tumor behavior involving epithelial-mesenchymal transition via the p-akt/p-mtor pathway in esophageal squamous cell carcinoma [J]. J Cancer Res Clin Oncol, 2017, 143(12): 2413-2424.
[11]	Suzuki T, Shimada H, Nanami T, et al. Hyperfibrinogenemia is associated with inflammatory mediators and poor prognosis in patients with gastric cancer [J]. Surgery today, 2016, 46(12): 1394-1401.
[12]	Luo Y, Kim HS. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: A cohort study and meta-analysis [J]. J Gynecol Oncol, 2017, 28(3): e36.
[13]	Liu Z, Guo H, Gao F, et al. Fibrinogen and d-dimer levels elevate in advanced hepatocellular carcinoma: High pretreatment fibrinogen levels predict poor outcomes [J]. Hepatol res, 2017, 47(11): 1108-1117.
[14]	Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells [J]. Blood, 2000, 96(10): 3302-3309.
[15]	Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells [J]. Best Pract Res Clin Haematol, 2009, 22(1): 49-60.
[16]	Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation [J]. Blood, 2000, 96(12): 3772-3778.
[17]	Tanaka N, Kikuchi E, Matsumoto K, et al. Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma[J]. BJU int, 2013, 111(6): 857-864.
[18]	沈文，邓志雄，胡卫列, 等. 前列腺癌患者血浆纤维蛋白原的测定及临床意义[J]. 临床外科杂志, 2007, 15(8): 550-552.
[19]	Wang Y, Yin W, Wang Z, et al. Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy [J]. Prostate Cancer Prostatic Dis, 2016, 19(2): 209-215.

临床参数		值
年龄[岁，M（Q₂₅，Q₇₅）]		72（66，76）
BMI[kg/m²，(±s）]		22.9±3.3
FIB[g/L，M（Q₂₅，Q₇₅）]		3.52（2.97，4.35）
tPSA[μg/L，M（Q₂₅，Q₇₅）]		25.74（10.40，97.95）
fPSA[μg/L，M（Q₂₅，Q₇₅）]		3.00（1.38，8.49）
f/tPSA[%，M（Q₂₅，Q₇₅）]		11.80（7.30，17.35）
Gleason评分[例（%）]		?
?	<7分	143（31.36）
?	7分	119（26.10）
?	>7分	194（42.54）
cT分期[例（%）]		?
?	≤cT2c	290（63.60）
?	> cT2c	166（36.40）
淋巴结转移[例（%）]		?
?	无	300（65.79）
?	有	156（34.21）
骨转移[例（%）]		?
?	无	272（59.65）
?	有	184（40.35）
危险度分级[例（%）]		?
?	低危	57（12.50）
?	中危	90（19.74）
?	高危	309（67.76）

临床参数		值
年龄[岁，M（Q₂₅，Q₇₅）]		72（66，76）
BMI[kg/m²，(±s）]		22.9±3.3
FIB[g/L，M（Q₂₅，Q₇₅）]		3.52（2.97，4.35）
tPSA[μg/L，M（Q₂₅，Q₇₅）]		25.74（10.40，97.95）
fPSA[μg/L，M（Q₂₅，Q₇₅）]		3.00（1.38，8.49）
f/tPSA[%，M（Q₂₅，Q₇₅）]		11.80（7.30，17.35）
Gleason评分[例（%）]		?
?	<7分	143（31.36）
?	7分	119（26.10）
?	>7分	194（42.54）
cT分期[例（%）]		?
?	≤cT2c	290（63.60）
?	> cT2c	166（36.40）
淋巴结转移[例（%）]		?
?	无	300（65.79）
?	有	156（34.21）
骨转移[例（%）]		?
?	无	272（59.65）
?	有	184（40.35）
危险度分级[例（%）]		?
?	低危	57（12.50）
?	中危	90（19.74）
?	高危	309（67.76）

组别	例	FIB(g/L)
组别	例	M值	Q₂₅，Q₇₅	Z	P
BPH组	322	3.12	2.61，3.45	-9.121	<0.001
PCa组	456	3.52	2.97，4.35	-9.121	<0.001

组别	例	FIB(g/L)
组别	例	M值	Q₂₅，Q₇₅	Z	P
BPH组	322	3.12	2.61，3.45	-9.121	<0.001
PCa组	456	3.52	2.97，4.35	-9.121	<0.001

临床病理特征		例数	术前血浆纤维蛋白原水平[例（%）]		P值
临床病理特征		例数	≤4 g/L	>4 g/L	P值
年龄（岁）		?	?	?	<0.003
?	≤65	103	80（77.67）	23（22.33）	?
?	>65	353	218（61.76）	135（38.24）	?
BMI（kg/m²）		?	?	?	<0.715
?	< 24	288	190（65.97）	98（34.03）	?
?	≥24	168	108（64.29）	60（35.71）	?
tPSA（μg/L）		?	?	?	<0.001
?	<10	112	98（87.50）	14（12.50）	?
?	10～20	90	73（81.11）	17（18.89）	?
?	>20	254	127（50.00）	127（50.00）	?
f/tPSA（%）		?	?	?	<0.417
?	≤16	324	208（64.20）	116（35.80）	?
?	> 16	132	90（68.18）	42（31.82）	?
Gleason评分(分)		?	?	?	<0.001
?	<7	143	115（80.42）	28（19.58）	?
?	7	119	76（63.87）	43（36.13）	?
?	>7	194	107（55.15）	87（44.85）	?
cT分期		?	?	?	<0.002
?	≤cT2c	290	205（70.69）	85（29.31）	?
?	> cT2c	166	93（56.02）	73（43.98）	?
淋巴结转移		?	?	?	<0.991
?	无	300	196（65.33）	104（34.67）	?
?	有	156	102（65.38）	54（34.62）	?
骨转移		?	?	?	<0.248
?	无	272	172（63.24）	100（36.76）	?
?	有	184	126（68.48）	58（31.52）	?
危险度分级		?	?	?	<0.049
?	低危	57	29（50.88）	28（49.12）	?
?	中危	90	61（67.78）	29（32.22）	?
?	高危	309	208（67.31）	101（32.69）	?

Please choose a citation manager

Content to export